On January 5, 2010, Silence Therapeutics completed its merger with Intradigm. A new website for the merged company is under development. In the meantime, please visit www.silence-therapeutics.com.

THERAPEUTIC PLATFORM

Structural Modification

To further strengthen its position within the RNAi therapeutics space, Intradigm is actively exploring potentially valuable structural modifications for its proprietary siRNA sequences.

LINKS

View Intradigm’s recent press release announcing its in-licensing of key structural modification intellectual property
Learn more about the important work being done at the lab of Dr. Zamore which has led to the creation of the “Zamore Design Rules

These modifications are designed to improve both the efficacy and safety of these sequences, while also offering Intradigm an increased depth of patent protection. The company’s work in this area is bolstered by its exclusive in-licensing of a key patent portfolio, including the “Zamore Design Rules,” from the University of Massachusetts Medical School.